Theravance Biopharma, Inc. Appoints Shehnaaz Suliman to the Position of Senior Vice President, Corporate Development and Strategy
July 31, 2017 at 08:30 am EDT
Share
Theravance Biopharma, Inc. announced the appointment of Shehnaaz Suliman, MD, to the position of Senior Vice President, Corporate Development and Strategy. Dr. Suliman brings more than 15 years of senior-level experience in life science corporate strategy and business development, as well as product development, to her new role at Theravance Biopharma. In this position, she will be responsible for driving corporate and business development as well as portfolio management strategy with the goal of maximizing the value of the Company's novel therapeutic products. Dr. Suliman most recently held the position of Vice President Roche Partnering, in which she served as Roche's global business development leader for its immunology, infectious disease and specialty care franchises. In this role, Dr. Suliman led the overall business development strategy, including acquisitions and licensing activities in these areas.
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
THERAVANCE BIOPHARMA, INC. 
